-
Mashup Score: 1
Ruhnke et al. published a retrospective cohort study in Blood Advances validating the prognostic value of the 2022 ELN classification in patients with newly diagnosed AML.
Source: aml-hub.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 6CPX-351 in older patients with secondary or high-risk AML: Results from the phase II PETHEMA-LAMVYX trial - 2 month(s) ago
We summarize results from the phase II PETHEMA‐LAMVYX trial, which validated the findings from the pivotal trial of CPX-351 and provided new insights on efficacy and safety of CPX‐351 in older patients with sAML or high-risk AML.
Source: aml-hub.comCategories: General Medicine News, Oncologists1Tweet-
New publication 📝 Results from the phase II PETHEMA-LAMVYX trial published in @JournalCancer provide new insights on efficacy and safety of CPX‐351 in older patients with secondary or high-risk AML. Learn more: https://t.co/m9XX6pto7j #AMLsm #MedNews #MedEd @ArboliEduardo https://t.co/UF57uHYEcL
-
-
Mashup Score: 4GIMEMA AML1310 trial: 6-year update on risk-adapted, MRD-directed therapy for younger patients with AML - 2 month(s) ago
We summarize 6-year updated results from the phase II GIMEMA AML 1310 trial assessing risk-adapted, MRD-oriented post-remission therapy in patients with AML.
Source: aml-hub.comCategories: General Medicine News, Oncologists1Tweet-
New publication 📝 6-year updated results from the phase II GIMEMA AML1310 trial published in @BloodAdvances show that risk-adapted, MRD-directed therapy is feasible in younger patients with AML. Read more: https://t.co/NOi7Ha0xZK #AMLsm #MedNews #MedEd https://t.co/geZfEyGy4s
-
New publication 📝 Results from a retrospective cohort study published in @BloodAdvances show that reclassification according to ELN 2022 risk stratification improved the prognostic distinction for OS in patients with ND AML. More: https://t.co/krypDrt2I2 #AMLsm #MedNews #MedEd https://t.co/vkNLS9BmLo